MCL1 and hepatocellular carcinoma: HBV-associated HCC shows significant miR-193b downregulation, driving sorafenib resistance through myeloid cell leukemia-1 (Mcl-1) overexpression [206], whereas HCV-related HCC exhibits miR-193b upregulation and Mcl-1 downregulation, which enhances therapeutic sorafenib sensitivity [207].